Purchase this article with an account.
A. Minamoto, G. Hoppe, K. Talcott, H. Tanimura, J. Sears; Triamcinolone Acetonide Decreases IL–6 Induced VEGF Secretion from Human Cultured RPE cells. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3213.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Intravitreal triamcinolone acetonide (TA) is an effective therapy that decreases retinal thickness in patients with cystoid edema secondary to ocular disease associated with ischemia and/or inflammation. Interleukin–6 (IL–6) is an inflammatory cytokine that is increased in company with VEGF in the vitreous and aqueous of diabetic patients with macular edema. We hypothesized that TA affects IL–6 induced VEGF secretion in cultured human retinal pigment epithelium. Methods: A dose response and time course of IL–6 induced VEGF secretion was measured in ARPE–19 cells. VEGF concentration in conditioned medium was determined by ELISA. Monolayers of ARPE–19 cells were grown to confluence and placed in serum–free media for 48 hours and then stimulated with recombinant IL–6 (100ng/ml). TA was added 24 hours prior to IL–6 stimulation at concentration 1 µM. Results: IL–6 induced a three–fold increase in VEGF secretion from ARPE–19 cells. The time course was linear over 24 hours and 50 ng/ml a saturating concentration. TA reduced the IL–6 effect on VEGF secretion by 50%. Conclusions: IL–6 induces VEGF secretion from ARPE–19 cells. Pre–incubation with TA reduces VEGF secretion induced by IL–6. Blockade of IL–6 signal transduction by specific inhibitors may offer an alternative mechanism of reducing VEGF secretion.
This PDF is available to Subscribers Only